A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

(2009) J.-L. Harousseau et al.   BLOOD

Mechanism of action of lenalidomide in hematological malignancies

(2009) Venumadhav Kotla et al.   Journal of Hematology & Oncology

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

(2009) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13

(2008) T. A. Fehniger et al.   BLOOD

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

(2008) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY